Email ID
Password
Scrip   
Novo Nordisk to pay ZymoGenetics up to $182 million for IL-21 MAb
08 December 2009
Eleanor Malone

Novo Nordisk has paid ZymoGenetics $24 million up front and pledged up to a further $157.5 million in milestone payments for a pre-IND fully human monoclonal antibody and related IP rights.

Novo Nordisk has licensed an anti-interleukin-21 monoclonal antibody (anti-IL-21 MAb) targeting autoimmune...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36